Boceprevir for untreated chronic HCV genotype 1 infection

New England Journal of Medicine

Volumn 364, Issue 13, 2011, Pages 1195-1206

  Poordad, Fred ^a,l   McCone, Jonathan ^b,l   Bacon, Bruce R ^c,l   Bruno, Savino ^d,l   Manns, Michael P ^e   Sulkowski, Mark S ^f,l   Jacobson, Ira M ^g,l   Reddy, K Rajender ^h,l   Goodman, Zachary D ⁱ   Boparai, Navdeep ^j   DiNubile, Mark J ^j   Sniukiene, Vilma ^j   Brass, Clifford A ^j   Albrecht, Janice K ^j   Bronowicki, Jean Pierre ^k,l   Colombato, L ^l   Curciarello, J ^l   Silva, M ^l   Tanno, H ^l   Terg, R ^l   Adler, M ^l   Langlet, P ^l   Lasser, L ^l   Nevens, F ^l   Anderson, F ^l   Bailey, R ^l   Bilodeau, M ^l   Cooper, C ^l   Feinman, S V ^l   Heathcote, J ^l   Levstik, M ^l   Ramji, A ^l   Sherman, M ^l   Shafran, S ^l   Yoshida, E ^l   Achim, A ^l   Ben Ali, S ^l   Bigard, M A ^l   Bonny, C ^l   Bourliere, M ^l   Boyer Darrigrand, N ^l   Canva, V ^l   Couzigou, P ^l   De Ledinghen, V ^l   Guyader, D ^l   Hezode, C ^l   Larrey, D ^l   Latournerie, M ^l   Marcellin, P ^l   Mathurin, P ^l   Maynard Muet, M ^l   Moussalli, J ^l   Poupon, R ^l   Poynard, T ^l   Serfaty, L ^l   Tran, A ^l   Trepo, C ^l   Truchi, R ^l   Zarski, J P ^l   Berg, T ^l   Dikopoulos, N ^l   Eisenbach, C ^l   Galle, P R ^l   Gerken, G ^l   Goeser, T ^l   Gregor, M ^l   Klass, D ^l   Kraus, M R ^l   Niederau, C ^l   Schlaak, J F ^l   Schmid, R ^l   Thies, P ^l   Schmidt, K ^l   Thimme, R ^l   Weidenbach, H ^l   Zeuzem, S ^l   Angelico, M ^l   Carosi, G ^l   Craxi A ^l   Mangia, A ^l   Pirisi, M ^l   Rizzetto, M ^l   Taliani, G ^l   Zignego, A L ^l   Reesink, H W ^l   Serejo, F ^l   Reymunde, A ^l   Rosado, B ^l   Torres, E ^l   Barcena Marugan, R ^l   De La Mata, M ^l   Calleja, J L ^l   Castellano, G ^l   Diago, M ^l   Esteban, R ^l   Fernandez Rodriguez, C ^l   Sanchez Tapias, J ^l   Serra Desfilis, M A ^l   Afdhal, N ^l   Al Osaimi, A ^l   Balart, L ^l   Bennett, M ^l   Bernstein, D ^l   Black, M ^l   Bowlus, C ^l   Boyer, T ^l   Dalke, D ^l   Davis, C ^l   Davis, G ^l   Davis, M ^l   Everson, G ^l   Felizarta, F ^l   Flamm, S ^l   Freilich, B ^l   Galati, J ^l   Galler, G ^l   Ghalib, R ^l   Gibas, A ^l   Godofsky, E ^l   Gordon, F ^l   Gordon, S ^l   Gross, J ^l   Harrison, S ^l   Herrera, J ^l   Herrine, S ^l   Hu, K Q ^l   Imperial, J ^l   Jones, D ^l   Kilby, A ^l   King, J ^l   Koch, A ^l   Kowdley, K ^l   Krawitt, E ^l   Kwo, P ^l   Lambiase, L ^l   Lawitz, E ^l   Lee, W ^l   Levin, J ^l   Levine, R ^l   Li, X ^l   Lok, A ^l   Luketic, V ^l   Mailliard, M ^l   McHutchison, J ^l   Mikolich, D ^l   Morgan, T ^l   Muir, A ^l   Nelson, Don ^l   Nunes, F ^l   Nyberg, A ^l   Nyberg, L ^l   Pandya, P ^l   Pauly, M P ^l   Peine, C ^l   Poleynard, G ^l   Pound, D ^l   Poulos, J ^l   Rabinovitz, M ^l   Ravendhran, N ^l   Ready, J ^l   Reindollar, R ^l   Reuben, A ^l   Riley, T ^l   Rossaro, L ^l   Rubin, R ^l   Ryan, M ^l   Santoro, J ^l   Schiff, E ^l   Sepe, T ^l   Sherman, K ^l   Shiffman, M ^l   Sjogren, M ^l   Sjogren, R ^l   Smith, C ^l   Stein, L ^l   Strauss, R ^l   Szyjkowski, R ^l   Vargas, H ^l   Vierling, J ^l   Witt, D ^l   Yapp, R ^l   Younes, Z ^l   more..

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Gastroenterology Hepatology Certified Endoscopy Centers   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ INOVA FAIRFAX HOSPITAL   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EVENING DOSAGE; FATIGUE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDE; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 79953173221     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1010494     Document Type: Article

References (19)

1. Global surveillance and control of hepatitis C: report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
2. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16. (Pubitemid 30421405)
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
5. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93. [Erratum, N Engl J Med 2009;361:1027.]
6. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9. (Pubitemid 38988594)
7. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71. [Erratum, N Engl J Med 2004;351:1268.]
8. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009;360:257-67. [Erratum, N Engl J Med 2010;363:2474.]
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50. (Pubitemid 38988593)
10. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16.
11. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38. [Erratum, N Engl J Med 2009;361:1516.]
12. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303. [Erratum, N Engl J Med 2010;362:1647.]
13. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
14. Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1, 1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006;49:6074-86.
15. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-9. (Pubitemid 47436107)
16. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8. (Pubitemid 46627577)
17. Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010;52:1201-7.
18. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001;358:1241-2. (Pubitemid 33010853)
19. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9.